NEW YORK -- In a highly anticipated decision that could sway the fortunes of a handful of biotechnology companies, the federal patent office has turned back a challenge to patents covering a widely used method for editing genes. The office’s board of appeals ruled Wednesday that the Broad Institute of MIT and Harvard can keep patents it had been awarded for a technique called CRISPR that lets scientists alter DNA within cells. It turned back a challenge from the University of California, Berkeley. The school had filed its own CRISPR patent application in 2012 a few months before the Broad institute, but the Broad got its patents approved while Berkeley’s application is pending. The financial
Weekly Roundup: CRISPR-Cas9 patent case concludes, Mark Zuckerberg’s 5,000 word letter to global community
TechCrunch
Court Rules Against Berkeley In CRISPR Patent Case
